Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:
Late last month, Alnylam Pharmaceuticals reported positive, top-line results from its HELIOS-B clinical trial testing vutrisiran in an increasingly common heart disease called ATTR-CM. Detailed study results are being presented at the annual meeting of the European Society of Cardiology in late August. Those data should help answer lingering questions about vutrisiran’s benefit in ATTR-CM, including how the drug stacks up competitively against a rival medicine called acoramidis, made by BridgeBio Pharma.
Novo Nordisk is developing an obesity drug called monlunabant that is designed to block the cannabinoid receptor 1 (CB1) — a target in the body’s endocannabinoid system known to directly impact many physiological processes, including metabolism. Novo is already an obesity giant thanks to Wegovy, so expected results this quarter from a monlunabant Phase 2 study may only be incrementally important. But the data are likely to have much a greater impact on Skye Bioscience and Corbus Pharmaceuticals — smaller biotechs also developing their own CB1-targeted obesity drugs.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect